Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014 (2014), Article ID 932530, 7 pages
http://dx.doi.org/10.1155/2014/932530
Research Article

Peroxisome Proliferator-Activated Receptors Family Is Involved in the Response to Treatment and Mild Clinical Course in Patients with Ulcerative Colitis

1Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Vasco de Quiroga No. 15, Colonia Sección XVI, 14000 Mexico City, Mexico
2Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Vasco de Quiroga No. 15, Colonia Sección XVI, 14000 Mexico City, Mexico

Received 15 September 2014; Revised 4 November 2014; Accepted 4 November 2014; Published 8 December 2014

Academic Editor: Francisco Blanco-Vaca

Copyright © 2014 J. K. Yamamoto-Furusho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Jostins, S. Ripke, and R. Weersma, “Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease,” Nature, vol. 491, no. 7422, pp. 119–124, 2012. View at Publisher · View at Google Scholar
  2. J. Bassaganya-Riera, M. DiGuardo, M. Climent et al., “Activation of PPARγ and δ by dietary punicic acid ameliorates intestinal inflammation in mice,” British Journal of Nutrition, vol. 106, no. 6, pp. 878–886, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Abraham and J. H. Cho, “Inflammatory bowel disease,” The New England Journal of Medicine, vol. 361, no. 21, pp. 2066–2078, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Riccardi, E. Mazzon, S. Bruscoli et al., “Peroxisome proliferator-activated receptor-α modulates the anti-inflammatory effect of glucocorticoids in a model of inflammatory bowel disease in mice,” Shock, vol. 31, no. 3, pp. 308–316, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. K. W. Schroeder, W. J. Tremaine, and D. M. Ilstrup, “Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study,” The New England Journal of Medicine, vol. 317, no. 26, pp. 1625–1629, 1987. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Henriksen, J. Jahnsen, I. Lygren et al., “Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN Study),” Inflammatory Bowel Diseases, vol. 12, no. 7, pp. 543–550, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Simera, D. Moher, J. Hoey, K. F. Schulz, and D. G. Altman, “A catalogue of reporting guidelines for health research,” European Journal of Clinical Investigation, vol. 40, no. 1, pp. 35–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Annese, F. Rogai, A. Settesoldi, and S. Bagnoli, “PPARγ in inflammatory bowel disease,” PPAR Research, vol. 2012, Article ID 620839, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Rousseaux, B. Lefebvre, L. Dubuquoy et al., “Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ,” The Journal of Experimental Medicine, vol. 201, no. 8, pp. 1205–1215, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. J. K. Yamamoto-Furusho, A. Peñaloza-Coronel, F. Sánchez-Muñoz, R. Barreto-Zuñiga, and A. Dominguez-Lopez, “Peroxisome proliferator-activated receptor-gamma (PPAR-γ) expression is downregulated in patients with active ulcerative colitis,” Inflammatory Bowel Diseases, vol. 17, no. 2, pp. 680–681, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Dubuquoy, E. A. Jansson, S. Deeb et al., “Impaired expression of peroxisome proliferator-activated receptor γ in ulcerative colitis,” Gastroenterology, vol. 124, no. 5, pp. 1265–1276, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. J. D. Lewis, G. R. Lichtenstein, J. J. Deren et al., “Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial,” Gastroenterology, vol. 134, no. 3, pp. 688–695, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. Y.-T. Azuma, K. Nishiyama, Y. Matsuo et al., “PPARα contributes to colonic protection in mice with DSS-induced colitis,” International Immunopharmacology, vol. 10, no. 10, pp. 1261–1267, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Kohno, R. Suzuki, S. Sugie, and T. Tanaka, “Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands,” BMC Cancer, vol. 5, article 46, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Gry, R. Rimini, S. Strömberg et al., “Correlations between RNA and protein expression profiles in 23 human cell lines,” BMC Genomics, vol. 10, article 365, 2009. View at Publisher · View at Google Scholar · View at Scopus